Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 30;14(2):196.
doi: 10.3390/life14020196.

Mitochondria in Alzheimer's Disease Pathogenesis

Affiliations
Review

Mitochondria in Alzheimer's Disease Pathogenesis

Allison B Reiss et al. Life (Basel). .

Abstract

Alzheimer's disease (AD) is a progressive and incurable neurodegenerative disorder that primarily affects persons aged 65 years and above. It causes dementia with memory loss and deterioration in thinking and language skills. AD is characterized by specific pathology resulting from the accumulation in the brain of extracellular plaques of amyloid-β and intracellular tangles of phosphorylated tau. The importance of mitochondrial dysfunction in AD pathogenesis, while previously underrecognized, is now more and more appreciated. Mitochondria are an essential organelle involved in cellular bioenergetics and signaling pathways. Mitochondrial processes crucial for synaptic activity such as mitophagy, mitochondrial trafficking, mitochondrial fission, and mitochondrial fusion are dysregulated in the AD brain. Excess fission and fragmentation yield mitochondria with low energy production. Reduced glucose metabolism is also observed in the AD brain with a hypometabolic state, particularly in the temporo-parietal brain regions. This review addresses the multiple ways in which abnormal mitochondrial structure and function contribute to AD. Disruption of the electron transport chain and ATP production are particularly neurotoxic because brain cells have disproportionately high energy demands. In addition, oxidative stress, which is extremely damaging to nerve cells, rises dramatically with mitochondrial dyshomeostasis. Restoring mitochondrial health may be a viable approach to AD treatment.

Keywords: Alzheimer’s disease; electron transport chain; inflammation; mitochondria.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Diagram demonstrating the flow of electrons through the mitochondrial electron transport chain (ETC). Electrons initially enter the ETC by NADH at complex I, and FADH2 from complex II. Ubiquinone transports the electrons to complex III, and then through cytochrome (Cyt) C to complex IV where oxygen is reduced into water. A proton gradient pumped across the inner mitochondrial membrane caused by the translocation of protons synthesizes ATP.
Figure 2
Figure 2
Schematic representation of factors involved in mitochondrial dysfunction and AD: Mitochondrial dysfunction in the AD brain results in elevated oxidative stress, increased mitochondrial fragmentation, mitophagy, impaired mitochondrial trafficking, mitochondrial DNA damage, defective mitochondrial biogenesis and dynamics and reduced glucose metabolism. Accumulation of Aβ can contribute to mitochondrial oxidative stress while tau protein, present in extracellular tangles, can interfere with axonal movement of mitochondria.

References

    1. d’Errico P., Meyer-Luehmann M. Mechanisms of Pathogenic Tau and Aβ Protein Spreading in Alzheimer’s Disease. Front. Aging Neurosci. 2020;12:265. doi: 10.3389/fnagi.2020.00265. - DOI - PMC - PubMed
    1. Volloch V., Rits-Volloch S. Effect of Lecanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective. J. Alzheimers Dis. 2023;93:1277–1284. doi: 10.3233/JAD-230164. - DOI - PMC - PubMed
    1. Varadharajan A., Davis A.D., Ghosh A., Jagtap T., Xavier A., Menon A.J., Roy D., Gandhi S., Gregor T. Guidelines for pharmacotherapy in Alzheimer’s disease—A primer on FDA-approved drugs. J. Neurosci. Rural Pract. 2023;14:566–573. doi: 10.25259/JNRP_356_2023. - DOI - PMC - PubMed
    1. Birnbaum J.H., Wanner D., Gietl A.F., Saake A., Kündig T.M., Hock C., Nitsch R.M., Tackenberg C. Oxidative stress and altered mitochondrial protein expression in the absence of amyloid-β and tau pathology in iPSC-derived neurons from sporadic Alzheimer’s disease patients. Stem Cell. Res. 2018;27:121–130. doi: 10.1016/j.scr.2018.01.019. - DOI - PubMed
    1. Tapias V., González-Andrés P., Peña L.F., Barbero A., Núñez L., Villalobos C. Therapeutic Potential of Heterocyclic Compounds Targeting Mitochondrial Calcium Homeostasis and Signaling in Alzheimer’s Disease and Parkinson’s Disease. Antioxidants. 2023;12:1282. doi: 10.3390/antiox12061282. - DOI - PMC - PubMed

LinkOut - more resources